Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Long-Term Dynamics of Three Dimensional Telomere Profiles in Circulating Tumor Cells in High-Risk Prostate Cancer Patients Undergoing Androgen-Deprivation and Radiation Therapy.

Wark L, Quon H, Ong A, Drachenberg D, Rangel-Pozzo A, Mai S.

Cancers (Basel). 2019 Aug 14;11(8). pii: E1165. doi: 10.3390/cancers11081165.

2.

Distinct 3D Structural Patterns of Lamin A/C Expression in Hodgkin and Reed-Sternberg Cells.

Contu F, Rangel-Pozzo A, Trokajlo P, Wark L, Klewes L, Johnson NA, Petrogiannis-Haliotis T, Gartner JG, Garini Y, Vanni R, Knecht H, Mai S.

Cancers (Basel). 2018 Aug 24;10(9). pii: E286. doi: 10.3390/cancers10090286.

3.

Dynamics of three-dimensional telomere profiles of circulating tumor cells in patients with high-risk prostate cancer who are undergoing androgen deprivation and radiation therapies.

Wark L, Klonisch T, Awe J, LeClerc C, Dyck B, Quon H, Mai S.

Urol Oncol. 2017 Mar;35(3):112.e1-112.e11. doi: 10.1016/j.urolonc.2016.10.018. Epub 2016 Dec 10.

4.

High Mobility Group A2 protects cancer cells against telomere dysfunction.

Natarajan S, Begum F, Gim J, Wark L, Henderson D, Davie JR, Hombach-Klonisch S, Klonisch T.

Oncotarget. 2016 Mar 15;7(11):12761-82. doi: 10.18632/oncotarget.6938.

5.

Three-dimensional telomere dynamics in follicular thyroid cancer.

Wark L, Danescu A, Natarajan S, Zhu X, Cheng SY, Hombach-Klonisch S, Mai S, Klonisch T.

Thyroid. 2014 Feb;24(2):296-304. doi: 10.1089/thy.2013.0118. Epub 2013 Sep 4.

6.

Heterozygous mutations in the PALB2 hereditary breast cancer predisposition gene impact on the three-dimensional nuclear organization of patient-derived cell lines.

Wark L, Novak D, Sabbaghian N, Amrein L, Jangamreddy JR, Cheang M, Pouchet C, Aloyz R, Foulkes WD, Mai S, Tischkowitz M.

Genes Chromosomes Cancer. 2013 May;52(5):480-94. doi: 10.1002/gcc.22045. Epub 2013 Jan 23.

PMID:
23341105
7.

Nuclear remodeling as a mechanism for genomic instability in cancer.

Gadji M, Vallente R, Klewes L, Righolt C, Wark L, Kongruttanachok N, Knecht H, Mai S.

Adv Cancer Res. 2011;112:77-126. doi: 10.1016/B978-0-12-387688-1.00004-1. Review.

PMID:
21925302
8.

Homozygous BUB1B mutation and susceptibility to gastrointestinal neoplasia.

Rio Frio T, Lavoie J, Hamel N, Geyer FC, Kushner YB, Novak DJ, Wark L, Capelli C, Reis-Filho JS, Mai S, Pastinen T, Tischkowitz MD, Marcus VA, Foulkes WD.

N Engl J Med. 2010 Dec 30;363(27):2628-37. doi: 10.1056/NEJMoa1006565.

9.

Nuclear imaging in three dimensions: a unique tool in cancer research.

Klonisch T, Wark L, Hombach-Klonisch S, Mai S.

Ann Anat. 2010 Sep 20;192(5):292-301. doi: 10.1016/j.aanat.2010.07.007. Epub 2010 Aug 6. Review.

PMID:
20800459
10.

Nucleosomal response, immediate-early gene expression and cell transformation.

Davie JR, Drobic B, Perez-Cadahia B, He S, Espino PS, Sun JM, Chen HY, Dunn KL, Wark L, Mai S, Khan DH, Davie SN, Lu S, Peltier CP, Delcuve GP.

Adv Enzyme Regul. 2010;50(1):135-45. doi: 10.1016/j.advenzreg.2009.10.008. Epub 2009 Nov 4. Review. No abstract available.

PMID:
19895841
11.

Increased genomic instability and altered chromosomal protein phosphorylation timing in HRAS-transformed mouse fibroblasts.

Dunn KL, He S, Wark L, Delcuve GP, Sun JM, Yu Chen H, Mai S, Davie JR.

Genes Chromosomes Cancer. 2009 May;48(5):397-409. doi: 10.1002/gcc.20649.

PMID:
19191262
12.

Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response.

Gorrini C, Squatrito M, Luise C, Syed N, Perna D, Wark L, Martinato F, Sardella D, Verrecchia A, Bennett S, Confalonieri S, Cesaroni M, Marchesi F, Gasco M, Scanziani E, Capra M, Mai S, Nuciforo P, Crook T, Lough J, Amati B.

Nature. 2007 Aug 30;448(7157):1063-7.

PMID:
17728759

Supplemental Content

Loading ...
Support Center